The Conversation (0)
IntelliCell BioSciences, Inc. (OTCQB:SVFC), a regenerative medicine company utilizing adult autologous vascular fraction cells derived from the blood vessels found in adipose tissue, received notice of publication for its technology patent in Hong Kong for “Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use thereof.”
IntelliCell BioSciences, Inc. (OTCQB:SVFC), a regenerative medicine company utilizing adult autologous vascular fraction cells derived from the blood vessels found in adipose tissue, received notice of publication for its technology patent in Hong Kong for “Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use thereof.”
IntelliCell BioSciences CEO, Dr. Victor, said:
This is wonderful news in that we are expanding our international patent portfolio to further protect our patent around the world. And I believe that we are now in the phase of our international patent process to reach out and seek international partners to whom we would license our technology and cellular labs and start generating international revenues.
Click here to read the IntelliCell BioSciences, Inc. (OTCQB:SVFC) press release
